Management of coronary artery disease in patients with aortic stenosis.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
27 01 2023
Historique:
pubmed: 17 12 2022
medline: 1 2 2023
entrez: 16 12 2022
Statut: epublish

Résumé

Aortic stenosis (AS) is the most common valvular heart disorder in the elderly population. As a result of the shared pathophysiological processes, AS frequently coexists with coronary artery disease (CAD). These patients have traditionally been managed through surgical aortic valve replacement (SAVR) and coronary artery bypass grafting. However, increasing body of evidence supports transcatheter aortic valve implantation (TAVI) as an alternative treatment for severe AS across the spectrum of operative risk. This has created the potential for treating AS and concurrent CAD completely percutaneously. In this review we consider the evidence guiding the optimal management of patients with severe AS and CAD. While invasive coronary angiography plays a central role in detecting CAD in patients with AS undergoing surgery or TAVI, the benefits of complementary functional assessment of coronary stenosis in the context of AS have not been fully established. Although the indications for revascularisation of significant proximal CAD in SAVR patients have not recently changed, routine revascularisation of all significant CAD before TAVI in patients with minimal angina is not supported by the latest evidence. Several ongoing trials will provide new insights into physiology-guided revascularisation in TAVI recipients. The role of the heart team remains essential in this complex patient group, and if revascularisation is being considered careful evaluation of clinical, anatomical and procedural factors is essential for individualised decision-making.

Identifiants

pubmed: 36526337
pii: heartjnl-2022-321605
doi: 10.1136/heartjnl-2022-321605
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

322-329

Subventions

Organisme : British Heart Foundation
ID : FS/CRTF/22/24328
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Vitaliy Androshchuk (V)

Rayne Institute, BHF Centre of Research Excellence, King's College London, St Thomas' Hospital, Guy's and St Thomas' Hospitals NHS Trust, London, UK vitaliy.androshchuk@gstt.nhs.uk.

Tiffany Patterson (T)

Rayne Institute, BHF Centre of Research Excellence, King's College London, St Thomas' Hospital, Guy's and St Thomas' Hospitals NHS Trust, London, UK.

Simon R Redwood (SR)

Rayne Institute, BHF Centre of Research Excellence, King's College London, St Thomas' Hospital, Guy's and St Thomas' Hospitals NHS Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH